Sandoz U.S. President Peter Goldschmidt: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
In an interview at Novartis’ U.S. headquarters, Goldschmidt talked about the Novartis unit’s approach to launching the first biosimilar in the U.S., and the other future growth drivers for Sandoz, including complex generics like Glatopa.
You may also be interested in...
Biosimilar Pathway Quickly Becoming Crowded In U.S.
Interactive chart of growing 351(k) pipeline shows that while Phase III is dominated by big players, pure-play biosimilar companies are beginning to emerge.
Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible
FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.